The sponsor Adlai Nortye will host free dinner in Shanghai from 6-8 pm before webinar. Register for dinner ticket if you are in Shanghai!

About this event

Webinar Date:

China Time: Friday, Jul 23rd, 8-9:30 PM

US EST Time: Friday, Jul 23rd, 8-9:30 AM

US PST Time: Friday, Jul 23rd, 5-6:30 AM

Central European Time: Friday, Jul 23rd, 2-3:30 pm

Language: English, with Chinese simultaneous translation

Venue: Live Zoom Webinar, with in-person reception and dinner in Shanghai

Webinar Agenda

► Chairs:

  • Dr. Ye Guo, Tongji University East Hospital
  • Dr. Denis Soulieres, Centre de recherche du Centre. Hospitalier de l'Université de, Montréal

► Presentations:

ASCO Meeting Highlights in Non-squamous H&N cancer

  • Lisa F. Licitra,University of Milan

ASCO Meeting Highlights in HNSCC recurrent/metastatic

  • Barbara Burtness, Interim Associate Director for Diversity, Equity and Inclusion, Yale Cancer Center

ASCO Meeting Highlights in HNSCC locally advanced disease

  • Naomi Kiyota, Cancer Center, Kobe University Hospital

Panel Discussion

  • Dr. Denis Soulieres, Centre de recherche du Centre. Hospitalier de l'Université de, Montréal
  • Dr. Ye Guo, Tongji University East Hospital
  • Dr. Barbara Burtness, Interim Associate Director for Diversity, Equity and Inclusion, Yale Cancer Center
  • Dr. Lisa F. Licitra, University of Milan
  • Dr. Naomi Kiyota,Cancer Center, Kobe University Hospital
  • Dr. Muh-Hwa Yang, Taipei Veterans General Hospital

Speakers and Panelists Bio

Dr. Ye Guo, Tongji University East Hospital

Dr. Ye Guo, Deputy Director of the Oncology Department at Tongji University East Hospital;Deputy Secretary-General of Chinese Society of Clinical Oncology (CSCO), Chairman of H&N Cancer Committee (CSCO)

Dr. Ye Guo, MD, is the Deputy Director of the Oncology Department at Tongji University East Hospital in China.

He studied medicine in Shanghai Medical University in China and joined Fudan University Shanghai Cancer Center in 1998. From 2010, he was appointed Deputy Director of Medical Oncology Department and leaded the research team for H&N cancer and lymphoma. Currently, he focuses on the development of novel agent and acts as the Director of Phase I Trial Unit at Tongji University East Hospital in China.

Dr. Guo is the Deputy Secretary-General of Chinese Society of Clinical Oncology (CSCO), Chairman of H&N Cancer Committee (CSCO), member of the Standing Committee of Union of Chinese Lymphoma Investigators (UCLI), Vice Chairman of H&N Cancer Committee and Lymphoma Committee of Shanghai Anti-cancer Association.

Dr. Guo is involved in multiple key clinical trials of head and neck cancer as a principal investigator in China. He has published a large number of articles in international peer-reviewed journals.

Dr. Denis Soulieres, Centre de recherche du Centre. Hospitalier de l'Université de, Montréal

Dr Denis Soulières obtained his medical degree at Laval University and then pursued his training in pediatrics, pediatric and adult hematology and then pediatric and adult medical oncology at Université de Montréal. He completed his post-doctoral training in clinical development in Switzerland and the USA.

He practices as a haematologist and medical oncologist at the Centre Hospitalier de l’Université de Montréal, more specifically at Hôpital Notre-Dame. He treats patients with head and neck tumours, lung cancer patients as well as GU cancers patients. He heads the H&N site group which oversees the treatment of 600 new cases a year.

He was a member of the NCIC-CTG clinical trials committee for 8 years and is sits on the executive committee of the Canadian H&N site group. He is the director of the special haematology and molecular biology laboratory in his institution. His lab is a reverence lab for many acquired genetic anomalies (hemopathies, GIST, K-RAS, EGFR mutations, etc).

He is active in clinical research as principal investigator or co-investigator in more than 100 trials. He directed the Clinical Research Unit at the CHUM for 3 years. He also participates in or directs basic research studies in translational medicine for RCC, NSCLC, head and neck tumors as well as hemoglobinopathies and thalassemias.

Lisa F. Licitra,University of Milan

Dr. Lisa Licitra is Board-certified in medical oncology, with special expertise in the treatment of head and neck cancers. She is currently Interim Director of Medical Oncology Head and Neck Cancer Department at the Istituto Nazionale Tumori in Milan, Italy.

Dr Lisa Licitra has been involved in clinical and translational research in the field of head and neck cancer for over 25 years. She is conducting as PI several clinical studies but more importantly academic studies with original translational research. She has been recipient of several academic research grants on head and neck cancer; she was also awarded with the “Guido Venosta” Prize of AIRC and with the “Hubertus Wald Award” prize of University Cancer Center Hamburg.

Dr Licitra is actively involved in international education and research programmes for head and neck cancer through EORTC, ESMO, ESTRO as well as national societies like AIOM and AIOCC. She is honorary member of ESTRO.

She is a member of the Head and Neck Faculty of ESMO, Member of the ESMO Guidelines Committee, Co-founder and member, as medical oncologist, of the European Head and Neck Cancer Society.

Furthermore Dr Licitra is free-contract Professor at State University of Milan, a member of the Clinical Editorial Board of the Journal of Clinical Oncology, Editor of START – State-of-the-Art Oncology in Europe (www.startoncology.net) a project of Alleanza Contro il Cancro – Ministry of Health – Italy

Dr Licitra has written 20 book chapters and approximately 152 scientific articles.

Barbara Burtness, Interim Associate Director for Diversity, Equity and Inclusion, Yale Cancer Center

Barbara Burtness, MD is Professor of Medicine (Medical Oncology) at the Yale School of Medicine and Yale Cancer Center.

She serves as Co-Leader of the Developmental Therapeutics Program and the Disease Aligned Research Team Leader for Head and Neck Cancer. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the Eastern Cooperative Oncology Group Head and Neck Cancer Committee and leads national and international trials of targeted therapy in head and neck cancer.

She comes to Yale from Fox Chase Cancer Center, where she co-led the Developmental Therapeutics Program, was Chief of Head and Neck Oncology and served as Associate Director for Clinical Research.

Naomi Kiyota, Kobe University Hospital Cancer Center

Naomi Kiyota was born in 1973 and started his medical training in 1993, graduating in 1999 from the Faculty of Medicine, Kobe University, Japan.

He did his internal medicine training at the Osaka-fu Saiseikai Nakatsu Hospital from 1999 and became a board-certified specialist in internal medicine in 2005.

In that year he moved to the National Cancer Center Hospital East (NCCH-E), in Chiba, Japan, for 3-year training in the field of medical oncology. He then moved to the Department of Medical Oncology, Kobe University Hospital, as an assistant professor in 2008. Since 2017, he has been an associate professor of Kobe University Hospital Cancer Center.

His main field of interest is medical oncology, especially specialized in head and neck cancer (HNC), thyroid cancer (TC) and GI oncology. His main research area is the conduct of multi-institutional clinical trials for HNC and TC.

With respect to his activities in Japanese organizations, he has been a member of the Japanese Society of Medical Oncology (JSMO) and the Japanese Clinical Oncology Group (JCOG). He served as the secretary general of JSMO2016 annual meeting in Kobe. And he has been the group coordinator of JCOG Head and Neck Cancer Study Group (JCOG-HNCSG) since 2016.

He underwent short-time training at the University Hospital Antwerp under the tuition of Professor Jan B. Vermorken on June/2009. He has been participating in EORTC Head and Neck Group meeting since 2010. And he has been an active member of EORTC QOL group since 2014.

He has published over 100 peer-reviewed papers in major cancer journals and serves on 3 editorial boards and 3 reviewer boards.

He has engaged as a principal investigator for 6 investigator-initiated trials (IIT) and 17 corporate sponsored trial (CST) and as a sub-investigator for 20 CSTs since 2010.

Dr. Muh-Hwa Yang, Taipei Veterans General Hospital

  • Vice President, National Yang-Ming University (2017/12/29-2021/01/31)
  • Chair Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine (2016/08/01-present)
  • Acting Director, Institute of Clinical Medicine, National Yang-Ming University (2017/07/16-2018/07/15)
  • Director, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital 2015/11/01-present)
  • Director, Cancer Progression Center of Excellence, National Yang-Ming University (2014/08/01-present)
  • Adjunct Research Fellow, Genomic Research Center, Academia Sinica (2014/08/01-present)
  • Director, Immunity and Inflammation Research Center, National Yang-Ming University, Taipei, Taiwan (Aug 2013~Dec 2016)
  • Professor, Institute of Clinical Medicine, National Yang Ming University School of Medicine, Taipei, Taiwan (Aug 2013~Jul 2016)
  • Attending Physician, Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taiwan (Sep 2002~ Mar 2015)